Brendan Smith
Stock Analyst at TD Cowen
(0.24)
# 3,765
Out of 4,667 analysts
8
Total ratings
16.67%
Success rate
-18.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $6.36 | +57.23% | 1 | Sep 20, 2024 | |
| EXAI Exscientia | Downgrades: Hold | n/a | $4.84 | - | 2 | Aug 9, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $45.76 | +42.05% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $8.06 | +24.07% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $18.71 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $24.42 | - | 1 | Dec 5, 2022 |
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $6.36
Upside: +57.23%
Exscientia
Aug 9, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.84
Upside: -
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $45.76
Upside: +42.05%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $8.06
Upside: +24.07%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $18.71
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $24.42
Upside: -